Health Care Equipment

ZYNEX INC

SEC Ends Investigation of Zynex Without Enforcement Action

Zynex and Humana Reach Supplier Agreement

Zynex, Inc. to Focus on Developing and Selling Non-Invasive Medical Tools

Zynex Responds to Federal Suit Against Former Executives and Undertakes Leadership Reorganization

Zynex Inc. Secures $22.3 Million Debtor-in-Possession Loan

ZYXIQ.US released FY2025 Q3 earnings on November 17 (BJT), actual revenue USD 13.36 M (forecast USD 24.53 M), actual EPS USD -1.42

ZYNEX INC released FY2025 9 Months Earnings on November 17, 2025 (EST) with actual revenue of USD 62.23 M and EPS of USD -2.412

ZYNEX INC released FY2024 9 Months Earnings on November 17, 2025 (EST) with actual revenue of USD 146.38 M and EPS of USD 0.1086

Zynex Inc. released FY2024 Q3 earnings on November 17 (EST), actual revenue USD 49.97 M (forecast USD 50.83 M), actual EPS USD 0.07

Zynex Inc. released FY2024 Q2 earnings on July 31 (EST), actual revenue USD 49.88 M (forecast USD 52.09 M), actual EPS USD 0.0383

Zynex Inc. released FY2025 Semi-Annual Earnings on July 31 (EST), with actual revenue of USD 48.87 M and EPS of USD -0.9838

Zynex Inc. released FY2024 Semi-Annual Earnings on July 31 (EST), with actual revenue of USD 96.41 M and EPS of USD 0.0382

Zynex Inc. released FY2025 Q2 earnings on July 31 (EST), actual revenue USD 22.29 M (forecast USD 27.38 M), actual EPS USD -0.662

Zynex Inc. released FY2025 Q1 earnings on April 29 (EST), actual revenue USD 26.58 M (forecast USD 30.75 M), actual EPS USD -0.33

Zynex Inc. released FY2024 Q1 earnings on April 29 (EST), actual revenue USD 46.53 M (forecast USD 47.69 M), actual EPS USD 0.0003

ZYNEX INC released FY2024 Q4 earnings on March 11 (EST), actual revenue USD 45.97 M (forecast USD 53.65 M), actual EPS USD -0.0202

ZYXIQ.US released FY2023 Annual Earnings on March 11 (BJT), actual revenue USD 184.32 M (forecast USD 191.64 M), actual EPS USD 0.27

Zynex Inc. released FY2023 Q4 earnings on March 11 (EST), actual revenue USD 47.29 M (forecast USD 55.62 M), actual EPS USD 0.0361

ZYNEX INC released FY2024 earnings on March 11 (EST), actual revenue USD 192.35 M (forecast USD 200.04 M), actual EPS USD 0.09

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

MetaVia

MicroAlgo

Vida Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

ZYXIQ

Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. (OTCPK: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that Zynex made misleading statements regarding its revenue and compliance with industry regulations, leading to significant stock price declines. Investors who suffered losses between February 25, 2021, and December 15, 2025, are encouraged to contact the firm for legal options.

prnewswire

11:11 ETZYXIQ SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

ZYXI

Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. and reminds investors of the April 21, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm alleges that Zynex made misleading statements regarding its revenue and compliance with industry regulations, leading to significant stock price declines. Investors who suffered losses between February 25, 2021, and December 15, 2025, are encouraged to contact the firm for legal options.

Zynex

09:18 ETZYXIQ INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a fraudulent overbilling scheme. The lawsuit claims Zynex engaged in excessive medical supply shipments to inflate billings, leading to a significant loss for investors. The firm urges affected investors to submit their losses by April 21, 2026, to be considered for lead plaintiff status. The case highlights serious allegations against former executives, including health care and securities fraud, resulting in Zynex's delisting from Nasdaq.

14:26 ETZYXI SHAREHOLDER ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Zynex Emerges From Bankruptcy With New Ownership Structure

Tip Ranks

Zynex Emerges From Bankruptcy With New Ownership Structure

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a fraudulent overbilling scheme. The lawsuit claims Zynex engaged in excessive medical supply shipments to inflate billings, leading to a suspension of payments from its largest payor, Tricare. Former executives face criminal charges, and Zynex's practices resulted in significant losses for investors. A critical deadline for investors to act as Lead Plaintiff is April 21, 2026.

16:45 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a systematic overbilling scheme. The lawsuit claims Zynex engaged in excessive shipping of medical supplies to inflate billings, leading to a suspension of payments from its largest payor, Tricare. The firm is urging investors who suffered losses during the class period (February 25, 2021 - December 15, 2025) to submit their claims by April 21, 2026. Former executives face criminal charges for fraud.

12:31 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. (OTCPK: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that Zynex made false statements and engaged in fraudulent overbilling practices, leading to significant revenue shortfalls and stock price declines. Investors who suffered losses between February 25, 2021, and December 15, 2025, are encouraged to contact the firm for legal options.

20:52 ETZYXIQ DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

ZYNEX INC(ZYXIQ.US)

11:11 ETZYXIQ SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

09:18 ETZYXIQ INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026

14:26 ETZYXI SHAREHOLDER ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Zynex Emerges From Bankruptcy With New Ownership Structure

16:45 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

12:31 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

20:52 ETZYXIQ DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026